Table 1.
Patient demographics and baseline disease characteristics
| All evaluable patients (n=51) | |
|---|---|
| Median Age (range) | 56 (34–78) |
| %Male (n) | 1 (2%) |
| % Female (n) | 50 (98%) |
| ECOG PS | |
| 0 | 36 (70.6%) |
| 1 | 15 (29.4%) |
| 2 | 0 |
| Number of prior lines of therapy | |
| 1 | 13 (25.5%) |
| 2 | 27 (52.9%) |
| 3 | 6 (11.8%) |
| 4 | 1 (2.0%) |
| 5+ | 4 (8.0%) |
| Germline mutation status by BROCA | |
| No detected germline mutation detected | 33 (65.6%) |
| BRCA1 | 13 (25.4%) |
| BRCA2 | 1 (2.0%) |
| RAD51D | 1 (2.0%) |
| CHEK2 | 1 (2.0%) |
| FANCL | 1 (2.0%) |
| MSH6 | 1 (2.0%) |
| Primary diagnosis/histology | |
| Cervix/adenocarcinoma | 1 (2%) |
| Endometrial | 4 (8%) |
| • Endometrioid | 2 (4%) |
| • High grade serous | 2 (4%) |
| Small cell lung cancer | 1 (2%) |
| Ovarian, fallopian, primary peritoneal | 45 (88%) |
| • High grade serous | 38 (74%) |
| • Endometrioid | 3 (6%) |
| • Poorly differentiated adenocarcinoma | 1 (2%) |
| • Carcinosarcoma | 1 (2%) |
| • Mucinous (1) | 1 (2%) |
| • Clear cell (1) | 1 (2%) |
| Ovarian Cancer Cohort (n = 45) | |
| Number of prior regimens | |
| 1 | 7 (16%) |
| 2 | 11 (24%) |
| 3 | 9 (20%) |
| 4 | 5 (11%) |
| 5+ | 13 (29%) |
| Germline mutation status by BROCA | |
| No germline mutation detected | 29 (65%) |
| BRCA1 | 13 (29%) |
| BRCA2 | 1 (2%) |
| RAD51D | 1 (2%) |
| CHEK2 | 1 (2%) |